LHV finantsportaal

Foorum Investeerimine

FMTI - uus tõus tulekul

Kommentaari jätmiseks loo konto või logi sisse

  • Rubicon Global Research, LLC Reiterates its Strong-Buy Rating on Forbes Medi-Tech
    9:00a ET November 21, 2005 (Business Wire)
    Recent weakness in Forbes Medi-Tech (NASDAQ:FMTI) creates an excellent buying opportunity. FMTI shares have declined in recent days as investors struggle to digest the recent PIPE financing and the Company's 3rd quarter, September 2005 earnings release. Furthermore, the absence of new food contracts, and concerns over potential contract renewals on the nutraceutical side of the business have created some apparent nervousness among investors. We believe the weakness in the shares represents a severe overreaction to fundamental developments, and that the business is tracking to our financial expectation. As a result, we are maintaining our current model and investment thesis. Thus, we recommend investors utilize this opportunity to buy shares in this exciting play on the multi-billion dollar, fast-growing cholesterol lowering market.
  • Head uudised ühele Oliveri lemmikule

    ~Products Incorporating Reducol(tm) Destined for UK's Largest Retailer,
    Tesco Stores Ltd.~

    Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today
    announced Forbes' cholesterol-lowering ingredient, Reducol(tm), has
    been launched in the UK. The initial products carrying Reducol(tm) will
    be sold through the UK's largest retailer, Tesco Stores Ltd. (Tesco),
    under their own private label. In combination with Tesco, Forbes
    Medi-Tech will announce further details about this new line of
    cholesterol-lowering products early in the new year as they become
    available on store shelves.

    At a joint press conference held in London today, several speakers
    discussed the importance of good cholesterol health and the launch of
    the New Heart Healthy range of products with Reducol(tm). Speakers
    included: Gwyneth Dunwoody, British Member of Parliament; Dr. Peter
    Jones, Department of Food Science & Human Nutritional Sciences,
    University of Manitoba; Dr Saul Myerson, Clinical Lecturer in
    Cardiovascular Medicine, Oxford University; and Jane Griffin, State
    Registered Dietitian and published author.

Teemade nimekirja